CureVac (NASDAQ:CVAC) Shares Up 3.6% – What’s Next?

CureVac (NASDAQ:CVAC)’s share price shot up 3.6% during mid-day trading on Friday . The stock traded as high as $3.19 and last traded at $3.16. 170,744 shares traded hands during trading, a decline of 79% from the average session volume of 811,117 shares. The stock had previously closed at $3.05.

Analysts Set New Price Targets

Separately, JMP Securities reiterated a “market outperform” rating and issued a $16.00 price target on shares of CureVac in a research note on Monday, September 16th.

CureVac Price Performance

The company has a quick ratio of 6.19, a current ratio of 6.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $687.31 million, a P/E ratio of 5.58, a PEG ratio of 0.24 and a beta of 2.59. The company has a 50 day moving average of $2.86 and a two-hundred day moving average of $3.14.

Institutional Investors Weigh In On CureVac

A number of large investors have recently bought and sold shares of CVAC. Barclays PLC acquired a new position in shares of CureVac during the third quarter worth approximately $67,000. Public Employees Retirement System of Ohio bought a new stake in shares of CureVac during the third quarter valued at approximately $91,000. Jane Street Group LLC raised its position in shares of CureVac by 239.0% during the third quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock worth $235,000 after acquiring an additional 55,867 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in CureVac during the 3rd quarter valued at about $35,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of CureVac by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 43,143 shares of the company’s stock valued at $127,000 after acquiring an additional 16,792 shares during the last quarter. 17.26% of the stock is currently owned by institutional investors.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.